183 related articles for article (PubMed ID: 29437974)
21. Reply to Das et al., "TIM1 (HAVCR1): an Essential 'Receptor' or an 'Accessory Attachment Factor' for Hepatitis A Virus?".
Costafreda MI; Kaplan G
J Virol; 2019 Jun; 93(11):. PubMed ID: 31092685
[No Abstract] [Full Text] [Related]
22. Potent Cas9 Inhibition in Bacterial and Human Cells by AcrIIC4 and AcrIIC5 Anti-CRISPR Proteins.
Lee J; Mir A; Edraki A; Garcia B; Amrani N; Lou HE; Gainetdinov I; Pawluk A; Ibraheim R; Gao XD; Liu P; Davidson AR; Maxwell KL; Sontheimer EJ
mBio; 2018 Dec; 9(6):. PubMed ID: 30514786
[TBL] [Abstract][Full Text] [Related]
23. [Preparation and characteristics of cultured strains of hepatitis A virus from humans and monkeys].
Korzaia LI; Shevtsova ZV; Lapin BA; D'iachenko AG; Krylova RI
Vopr Virusol; 1997; 42(2):60-3. PubMed ID: 9182400
[TBL] [Abstract][Full Text] [Related]
24. Amantadine and Rimantadine Inhibit Hepatitis A Virus Replication through the Induction of Autophagy.
Sasaki-Tanaka R; Shibata T; Moriyama M; Okamoto H; Kogure H; Kanda T
J Virol; 2022 Sep; 96(18):e0064622. PubMed ID: 36040176
[TBL] [Abstract][Full Text] [Related]
25. A pathogenic picornavirus acquires an envelope by hijacking cellular membranes.
Feng Z; Hensley L; McKnight KL; Hu F; Madden V; Ping L; Jeong SH; Walker C; Lanford RE; Lemon SM
Nature; 2013 Apr; 496(7445):367-71. PubMed ID: 23542590
[TBL] [Abstract][Full Text] [Related]
26. Characterization of anti-idiotypic antibodies mimicking antibody- and receptor-binding sites on hepatitis A virus.
Kiyohara T; Totsuka A; Yoneyama T; Ishii K; Ito T; Wakita T
Arch Virol; 2009; 154(8):1263-9. PubMed ID: 19578927
[TBL] [Abstract][Full Text] [Related]
27. Iminosugar Glucosidase Inhibitors Reduce Hepatic Inflammation in Hepatitis A Virus-Infected
Misumi I; Li Z; Sun L; Das A; Shiota T; Cullen J; Zhang Q; Whitmire JK; Lemon SM
J Virol; 2021 May; 95(11):e0005821. PubMed ID: 33692213
[TBL] [Abstract][Full Text] [Related]
28. Efficient neutralizing activity of cocktailed recombinant human antibodies against hepatitis A virus infection in vitro and in vivo.
Cao J; Meng S; Li C; Ji Y; Meng Q; Zhang Q; Liu F; Li J; Bi S; Li D; Liang M
J Med Virol; 2008 Jul; 80(7):1171-80. PubMed ID: 18461629
[TBL] [Abstract][Full Text] [Related]
29. Determining antigen specificity of a monoclonal antibody using genome-scale CRISPR-Cas9 knockout library.
Zotova A; Zotov I; Filatov A; Mazurov D
J Immunol Methods; 2016 Dec; 439():8-14. PubMed ID: 27664857
[TBL] [Abstract][Full Text] [Related]
30. [Spontaneous and experimental hepatitis A in Papio hamadryas].
Korzaia LI; Shevtsova ZV; Dzhelieva ZN; Krylova RI; Belova EG; Chalian VG
Vopr Virusol; 1992; 37(4):187-91. PubMed ID: 1335190
[TBL] [Abstract][Full Text] [Related]
31. Replication-competent human adenovirus 11p vectors can propagate in Vero cells.
Gokumakulapalle M; Mei YF
Virology; 2016 Aug; 495():42-51. PubMed ID: 27176913
[TBL] [Abstract][Full Text] [Related]
32. Human membrane protein Tim-3 facilitates hepatitis A virus entry into target cells.
Sui L; Zhang W; Chen Y; Zheng Y; Wan T; Zhang W; Yang Y; Fang G; Mao J; Cao X
Int J Mol Med; 2006 Jun; 17(6):1093-9. PubMed ID: 16685421
[TBL] [Abstract][Full Text] [Related]
33. HAVCR1 expression might be a novel prognostic factor for gastric cancer.
Liu L; Song Z; Zhao Y; Li C; Wei H; Ma J; Du Y
PLoS One; 2018; 13(11):e0206423. PubMed ID: 30388143
[TBL] [Abstract][Full Text] [Related]
34. Persistently infected cultures as a source of hepatitis A virus.
Simmonds RS; Szücs G; Metcalf TG; Melnick JL
Appl Environ Microbiol; 1985 Apr; 49(4):749-55. PubMed ID: 2988436
[TBL] [Abstract][Full Text] [Related]
35. Opposing Roles of Double-Stranded RNA Effector Pathways and Viral Defense Proteins Revealed with CRISPR-Cas9 Knockout Cell Lines and Vaccinia Virus Mutants.
Liu R; Moss B
J Virol; 2016 Sep; 90(17):7864-79. PubMed ID: 27334583
[TBL] [Abstract][Full Text] [Related]
36. A simple and rapid Hepatitis A Virus (HAV) titration assay based on antibiotic resistance of infected cells: evaluation of the HAV neutralization potency of human immune globulin preparations.
Konduru K; Virata-Theimer ML; Yu MY; Kaplan GG
Virol J; 2008 Dec; 5():155. PubMed ID: 19094229
[TBL] [Abstract][Full Text] [Related]
37. Growth of hepatitis A virus in a mouse liver cell line.
Feigelstock DA; Thompson P; Kaplan GG
J Virol; 2005 Mar; 79(5):2950-5. PubMed ID: 15709014
[TBL] [Abstract][Full Text] [Related]
38. RIG-I is responsible for activation of type I interferon pathway in Seneca Valley virus-infected porcine cells to suppress viral replication.
Li P; Zhang X; Cao W; Yang F; Du X; Shi Z; Zhang M; Liu X; Zhu Z; Zheng H
Virol J; 2018 Oct; 15(1):162. PubMed ID: 30352599
[TBL] [Abstract][Full Text] [Related]
39. Alteration of hepatitis A virus (HAV) particles by a soluble form of HAV cellular receptor 1 containing the immunoglobin-and mucin-like regions.
Silberstein E; Xing L; van de Beek W; Lu J; Cheng H; Kaplan GG
J Virol; 2003 Aug; 77(16):8765-74. PubMed ID: 12901378
[TBL] [Abstract][Full Text] [Related]
40. [Application of clustered regularly interspaced short palindromic repeats- associated protein 9 gene editing technology for treatment of HBV infection].
Wang YD; Liang QF; Li ZY; Zhao CY
Zhonghua Gan Zang Bing Za Zhi; 2018 Nov; 26(11):860-864. PubMed ID: 30616324
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
